Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Radiation Injuries 1Mixed Tumor, Mesodermal 1Gallbladder Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Clinical Stage I Gastric Cancer AJCC v8 1Breast Neoplasms 1

Interventions

Gemcitabine 31Cisplatin 22pembrolizumab 21Magnetic Resonance Spectroscopy 18Specimen Handling 16durvalumab 11Mitomycin 10enfortumab vedotin 9avelumab 9Cystoscopy 9Nivolumab 8Fluorouracil 8Carboplatin 8Radiation 7Cystectomy 7atezolizumab 5Transurethral Resection of Bladder 5Radiotherapy 5Mitozytrex 5Immunoglobulin G 5Docetaxel 5Disulfides 5Biopsy 5tremelimumab 4sacituzumab govitecan 4erdafitinib 4dehydroftorafur 4Platinum 41,2-diaminocyclohexaneplatinum II citrate 4disitamab vedotin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × Lymph Node Excision × 90 days × Clear all
NCT05581589 2026-04-27

Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer

University of Washington

Phase 2 Terminated
4 enrolled 13 charts
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡